Event category: Concurrent Session

Lead management remains an important part of contemporary electrophysiologic care. While extraction tools have relied on blunt mechanical dissection, rotational cutting tools, laser assisted technologies, and snares, new innovations are on the horizon. This session will explore the key opportunities for innovation in lead extraction procedures.

Pulsed field ablation is the energy modality of choice in catheter ablation of atrial fibrillation. While early studies suggest that PFA has significant advantages in the ventricle, ventricular PFA remains an area of intense innovation and discovery. This session will explore the next steps, challenges, and opportunities for PFA in ventricular ablation both today and in the future.

This session will explore how the non-verbal internal reasoning states of AI models will change and impact clinical care. In this dynamic session, the challenges and opportunities for latent intelligence in future EP care will be reviewed and debated with traditional human intelligence and judgment.

The vast majority of minimally invasive EP techniques focus on endocardial approaches, however, there are tremendous opportunities to improve existing and pioneer novel interventions that can be targeted to the pericardial space and the epicardium. This session will focus on emerging therapeutics targeting the mediastinum and epicardial space.

Leadless pacing continues to expand and evolve in clinical practice. We may be approaching the end of the beginning for leadless pacing and entering a new phase of innovation. This session will explore what the key next steps for leadless pacing are, including physiologic pacing, optimal device-device interactions, and options for long-term leadless pacing.

Nanoparticles are used in cardiac electrophysiology to restore electrical conduction, target drug delivery, and modulate cellular excitability. This session will investigate how these therapies can be developed, improved, and applied in the future to enhance clinical care and improve outcomes. The session will cover several topics including, but not limited to conductive nanomaterials and targeted therapeutics.

Catheter-based treatment of cardiac arrhythmias and Left Atrial Appendage Occlusion has seen tremendous advances in the past decade, lastly with a stronger trend toward integrated concomitant procedures. This session will review where today's workflows are challenged using different guidance solutions as well as the trend toward more integrated and combined procedures, and the need for reliable, intuitive, and precise navigation as a key requirement for optimal treatment.

Artificial intelligence tools have proliferated in the literature and are beginning to emerge in the clinic and EP lab. They bring value, but how do we pay for them? This session will explore how reimbursement paradigms may need to evolve and innovate as well.

Oral medications have been the dominant form of outpatient pharmacotherapy in EP, but could that change? This session will examine how non-oral alternatives can bring value and improve care. The session will also discuss the challenges for non-traditional heart rhythm drug development.